Share on StockTwits

Dechra Pharmaceuticals plc (LON:DPH) has been given an average recommendation of “Buy” by the eight brokerages that are presently covering the company, Analyst Ratings Network reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is GBX 771.50 ($12.98).

A number of research firms have recently commented on DPH. Analysts at Investec reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 787 ($13.24) price target on the stock. Separately, analysts at N 1 Singer reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 760 ($12.78) price target on the stock. Finally, analysts at N+1 Singer reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 760 ($12.78) price target on the stock.

Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 0.95% during mid-day trading on Tuesday, hitting GBX 689.50. 30,399 shares of the company’s stock traded hands. Dechra Pharmaceuticals plc has a 1-year low of GBX 655.00 and a 1-year high of GBX 755.00. The stock has a 50-day moving average of GBX 686.1 and a 200-day moving average of GBX 690.1. The company’s market cap is £601.3 million.

Dechra Pharmaceuticals PLC is a United Kingdom-based veterinary pharmaceutical company. The Company is engaged in developing, manufacturing, distributing, selling and marketing of animal products to the veterinary industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.